Reappraisal of statin primary prevention trials: implications for identification of the statin-eligible primary prevention patient
Authors' conclusion
Results of primary prevention RCTs justify treatment of more subjects and lower risk subjects than current risk algorithm-based guidelines.
Study context
- Population
- Enrollees of RCTs cited in North American and European dyslipidaemia guidelines justifying primary prevention statins
- Comparison
- Statin eligibility by minimal RCT enrolment criteria vs by risk algorithms (Framingham, pooled cohort equation, SCORE2)
- Outcome
- Statin eligibility of patients meeting minimal RCT enrolment criteria by risk algorithms (Framingham, pooled cohort equation, SCORE2); enrollee characteristics
- Follow-up
- 10 year risk
Main finding
As reported in the abstract
Enrollee age
63.9 ± 8.9 years (mean ± SD)
Enrollee low density lipoprotein-cholesterol (LDL-C)
3.53 ± 0.91 mmol/L
Original publication
Reappraisal of statin primary prevention trials: implications for identification of the statin-eligible primary prevention patient. Eur J Prev Cardiol. Published 25 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →